Syngene announces 3rd year of STEM scholarship for women with RICH
This year, 40 women students are participating, selected through a rigorous process evaluating academic merit, research interest, and socio-economic background
This year, 40 women students are participating, selected through a rigorous process evaluating academic merit, research interest, and socio-economic background
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
Lupin and Zentiva sign license and supply agreement for commercializing Certolizumab
The first project will focus on developing an AI-based platform for the sterically guided design of bispecific antibodies
The pharmaceuticals laboratory supports North Asia with formulation development, reverse engineering, troubleshooting, and analysis for various dosage forms
India’s fertility rate has dropped to 1.9, below the replacement level of 2.1
The Stryker Mako Robotic System uses artificial intelligence to improve surgical accuracy with real-time guidance, personalized planning, and precise execution
The company showcased three core programs developed through this platform
These medicines are essential in preventing RhD immunisation during pregnancy
Commercial production is expected to begin soon
Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone
The wholly owned subsidiary will carry on the business of all types of research and development and other related services
The facility will manufacture 13,200 MTPA Benzyl Chloride, 9,600 MTPA Benzyl Alcohol, and 7,200 MTPA Benzaldehyde
The companies admitted taking part in the cartel in exchange for reduced fines but Alchem did not settle
The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells
atai and Beckley Psytech plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to finalize the Phase 3 trial design.
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
The company has confirmed that the deceased are 39
Subscribe To Our Newsletter & Stay Updated